Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 13/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 12/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310704 | 0.76 | CA1 (0.47) | CA12CA1CA2CA9 | |
| SCHEMBL2356493 | 0.76 | CA1 (0.47) | CA12CA1CA2CA9 | |
| SCHEMBL3315063 | 0.75 | HCRTR1 (0.36) | HCRTR2HCRTR1 | |
| SCHEMBL3314169 | 0.74 | HCRTR1 (0.34) | HCRTR2HCRTR1HTR2ACA12CA1 | |
| SCHEMBL3314165 | 0.73 | HCRTR1 (0.34) | HCRTR2HCRTR1HTR2A | |
| SCHEMBL14778972 | 0.72 | HCRTR1 (0.35) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL14784306 | 0.72 | HCRTR1 (0.35) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL11949272 | 0.70 | MAPK1 (0.42) | HTR2A | |
| SCHEMBL11949288 | 0.69 | PIK3CD (0.42) | HCRTR2HCRTR1HTR2ACA12CA1 | |
| SCHEMBL11949285 | 0.68 | HTR2A (0.51) | HTR2ACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232271-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, POLR2B | HCRTR2 3341/4885HCRTR1 1471/4885HTR2A 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.